Vacuum biopsy before surgery to check treatment response
Part of Cancer, Skin clinical trials.
This trial studies a special vacuum-assisted biopsy taken just before breast surgery to see how well pre-surgery (neoadjuvant) chemotherapy worked. It may help doctors understand whether patients truly had a complete or near-complete response on scans, which can guide next steps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have signed consent for the study before any study-specific steps
- You have one breast tumor (not multiple areas) confirmed as invasive breast cancer, with specific hormone test results (ER less than 10%)
- Your tumor started between 1 and 5 cm and has no spread to distant organs (M0), with lymph nodes allowed (any N)
- Before chemotherapy, a small marker “clip” was placed at the main tumor location
- After chemotherapy, your MRI scan shows complete or near-complete response (MRI is strongly preferred; ultrasound may be allowed)
- The area of the previous tumor “tumor bed” must be reachable for biopsy before surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a less invasive way to check for remaining breast cancer after chemotherapy, using a needle biopsy instead of surgery. The goal is to confirm that no cancer is left so that some patients might safely skip surgery or have a less extensive operation.
This trial tests a scanner that checks removed breast tissue during surgery to help surgeons remove all cancer the first time. If it works, fewer women may need a second operation.
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.